# Revelation Biosciences, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Revelation Biosciences, Inc). ## Overview Revelation Biosciences, Inc. is a U.S.-based clinical-stage life science company developing therapies built around its proprietary Gemini formulation of PHAD, an innate-immune modulator. Its pipeline includes programs for acute kidney injury, chronic kidney disease, post-surgical infection, and infection prevention in severe burn patients, with operations centered in San Diego, California. ## Products & services • Gemini-based therapeutic platform • GEM-AKI for acute kidney injury • GEM-CKD for chronic kidney disease • GEM-PSI for post-surgical infection • GEM-PBI for burn-patient infection prevention • PHAD-based licensed infection-prevention program - **Clinical-stage product candidates** (85%) — Gemini-based drug candidates being developed for kidney disease and infection-related indications. - **Licensed PHAD program** (15%) — A worldwide licensed program using PHAD for treating or preventing infections. - Gemini-based therapeutic platform - GEM-AKI for acute kidney injury - GEM-CKD for chronic kidney disease - GEM-PSI for post-surgical infection - GEM-PBI for burn-patient infection prevention - PHAD-based licensed infection-prevention program ## Customers Revelation does not yet sell approved products; its near-term counterparties are clinical investigators, contract research organizations, manufacturers, regulators, and licensing partners. If approved, its therapies would be used by physicians and hospitals treating acute kidney injury, chronic kidney disease, post-surgical infection, and severe burn patients. - **Clinical trial ecosystem** (primary) — Research sites, CROs, and vendors supporting preclinical and clinical development of Gemini programs. - **Hospital and specialist physicians** (primary) — Potential prescribers for AKI, CKD, post-surgical infection, and burn-related infection prevention. - **Licensing and collaboration partners** (secondary) — Partners that could help fund, develop, or commercialize PHAD-based programs. - **Regulatory and reimbursement stakeholders** (primary) — FDA and future payers that determine approval timing and market access. - Clinical trial sites and investigators running Gemini studies - Hospitals and physicians treating AKI and CKD patients - Hospital-based clinicians managing post-surgical infections - Burn centers treating severe burn patients at infection risk - Potential licensing and commercialization partners ## Geography The company is incorporated in Delaware and based in San Diego, California, with development activities centered in the United States. Its business is currently U.S.-focused, although the Vanderbilt license is worldwide and any eventual commercialization could extend beyond the U.S. - Incorporated in Delaware and headquartered in San Diego, California - Development and clinical operations are centered in the United States - Current programs are U.S.-based clinical development efforts - Vanderbilt license is worldwide, enabling future non-U.S. expansion ## Strategy Revelation’s strategy is to advance Gemini through clinical development across multiple indications while preserving optionality through licensing and partnerships. It also seeks to broaden its pipeline through internal development, acquisitions, and in-licensing, while relying on third parties for manufacturing and future commercialization. - **Advance GEM-AKI and GEM-CKD** (short-term) — These are the core clinical programs and the main path to value creation. - **Expand into infection-related indications** (medium-term) — Broadens the platform beyond kidney disease and increases pipeline optionality. - **Secure development funding and partners** (short-term) — Clinical-stage biotech requires external capital and collaboration to progress. - **Outsource manufacturing and future commercialization** (medium-term) — Reduces capital intensity and leverages specialized third-party capabilities. - Advance Gemini through clinical-stage development - Build a pipeline across kidney and infection indications - Use partnerships and licensing to extend development capacity - Rely on third-party manufacturing for clinical and commercial supply - Pursue additional in-licensing and acquisition opportunities ## Risks Revelation faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory delays, and dependence on external capital. Its business is also exposed to single-supplier and third-party manufacturing reliance, plus the possibility that licensing terms, milestone obligations, or commercialization plans do not progress as expected. - **Clinical development failure** [critical] — Gemini programs must prove safety and efficacy in human trials before approval. - **Regulatory delay or rejection** [high] — FDA review and trial oversight determine whether programs can advance. - **Capital dependence and dilution** [high] — The company funds operations through equity raises and may need more capital. - **Manufacturing and supply concentration** [high] — The company relies on third parties and has a single supplier for PHAD. - **Commercialization and reimbursement uncertainty** [medium] — Even approved drugs need market access, pricing, and adoption by physicians/payers. - No approved products and no commercial revenue base - Clinical trials may fail to show safety or efficacy - FDA review timing can delay development and approvals - Dependence on third-party manufacturing and a single supplier - Future financing may dilute shareholders or be unavailable ## Accounting As a clinical-stage biotech, Revelation expenses research and development as incurred, so trial activity directly drives reported losses. Investors should also watch warrant accounting, reverse stock split effects on share data, and fair-value measurements tied to financing instruments, all of which can materially affect reported results and equity presentation. - **Research and development expense recognition** — Drives operating loss timing and comparability across periods - **Warrant liability fair value** — Can materially affect reported earnings and balance sheet values - **Going concern and financing disclosures** — Important for assessing liquidity and continuity of operations - **Reverse stock split accounting presentation** — Impacts EPS, share price comparability, and market data - R&D is expensed as incurred, so trial spend hits earnings immediately - Clinical and preclinical payments may be capitalized until services are received - Warrants may be recorded as liabilities and remeasured at fair value - Reverse stock splits affect share counts and per-share comparability - Going-concern and financing disclosures are important for interpretation --- *Last updated: 2026-09-24T11:53:08.608358+00:00*